Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK …
T Chen, C Wang, Q Liu, Q Meng, H Sun… - Cancer biology & …, 2015 - Taylor & Francis
Multidrug resistance (MDR) is one of the major obstacles to the efficiency of cancer
chemotherapy, which often results from the overexpression of drug efflux transporters such …
chemotherapy, which often results from the overexpression of drug efflux transporters such …
[HTML][HTML] Repurposing tyrosine kinase inhibitors to overcome multidrug resistance in cancer: a focus on transporters and lysosomal sequestration
M Krchniakova, J Skoda, J Neradil, P Chlapek… - International journal of …, 2020 - mdpi.com
Tyrosine kinase inhibitors (TKIs) are being increasingly used to treat various malignancies.
Although they were designed to target aberrant tyrosine kinases, they are also intimately …
Although they were designed to target aberrant tyrosine kinases, they are also intimately …
Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib
The efflux transporters adenosine triphosphate (ATP)‐binding cassette (ABC) B1 and
ABCG2 have been demonstrated to interact with the tyrosine kinase inhibitors (TKIs) …
ABCG2 have been demonstrated to interact with the tyrosine kinase inhibitors (TKIs) …
Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?
Introduction: Anticancer tyrosine kinase inhibitors (TKIs) are small molecule hydrophobic
compounds designed to arrest aberrant signaling pathways in malignant cells. Multidrug …
compounds designed to arrest aberrant signaling pathways in malignant cells. Multidrug …
[HTML][HTML] Therapeutic drug monitoring and individualized medicine of dasatinib: focus on clinical pharmacokinetics and pharmacodynamics
S He, J Bian, Q Shao, Y Zhang, X Hao, X Luo… - Frontiers in …, 2021 - frontiersin.org
Dasatinib is an oral second-generation tyrosine kinase inhibitor known to be used widely in
Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and Ph+ acute …
Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and Ph+ acute …
[HTML][HTML] Tivantinib, A c-met inhibitor in clinical trials, is susceptible to ABCG2-mediated drug resistance
Tivantinib, also known as ARQ-197, is a potent non-ATP competitive selective c-Met inhibitor
currently under phase 3 clinical trial evaluation for liver and lung cancers. In this study, we …
currently under phase 3 clinical trial evaluation for liver and lung cancers. In this study, we …
The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2
Ponatinib is a novel tyrosine kinase inhibitor with potent activity against BCR-ABL with
mutations, including T315I, and also against fms-like tyrosine kinase 3. We tested …
mutations, including T315I, and also against fms-like tyrosine kinase 3. We tested …
In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2)
HEM Schwabedissen, HK Kroemer - Drug Transporters, 2011 - Springer
The breast cancer resistance protein (BCRP/ABCG2) is a member of the G-subfamiliy of the
ATP-binding cassette (ABC)-transporter superfamily. This half-transporter is assumed to …
ATP-binding cassette (ABC)-transporter superfamily. This half-transporter is assumed to …
Dual inhibitors as a new challenge for cancer multidrug resistance treatment
T Stanković, J Dinić, A Podolski-Renić… - Current Medicinal …, 2019 - ingentaconnect.com
Background: Dual-targeting in cancer treatment by a single drug is an unconventional
approach in relation to drug combinations. The rationale for the development of …
approach in relation to drug combinations. The rationale for the development of …
[HTML][HTML] Mechanisms of acquired resistance to tyrosine kinase inhibitors
Y Chen, L Fu - Acta Pharmaceutica Sinica B, 2011 - Elsevier
In recent years, structural and functional studies reveal that tyrosine kinases (TKs) act as the
essential components of signal transduction pathways that regulate cancer cell proliferation …
essential components of signal transduction pathways that regulate cancer cell proliferation …